Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin‐11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy
Open Access
- 29 May 2003
- Vol. 97 (12), 3099-3106
- https://doi.org/10.1002/cncr.11447
Abstract
BACKGROUND Previous research has shown oprelvekin (recombinant human interleukin‐11 [rhIL‐11]) to be effective in reducing the requirements for platelet transfusions after myelosuppressive chemotherapy in patients who have previously experienced thrombocytopenia. The economic consequences of the routine use of this platelet growth factor and the usual standard of platelet transfusions for prophylaxis of severe chemotherapy‐induced thrombocytopenia have not been compared. METHODS The authors constructed a decision‐analytic model to compare the alternatives of rhIL‐11 versus usual care using probability, outcome, and cost data from previously published clinical trials and their own institutional sources. They incorporated the costs of platelet transfusions and adverse events from rhIL‐11 into the analysis. Quality‐of‐life outcomes were not considered. The pharmacoeconomic analysis was based on the criterion of cost minimization from the payer's perspective. RESULTS The expected cost of the usual care strategy for prophylaxis of severe thrombocytopenia (transfusion when platelets < 20,000 μL−1) was $3495 for a 3‐week cycle of chemotherapy. The prophylactic rhIL‐11 strategy was more expensive, with an expected cost of $5328 over the same time period. Nonetheless, it was associated with fewer platelet transfusions, avoiding an average of 6.7 U compared with usual care. The savings from avoidance of platelet transfusion and adverse reactions to transfusion from the use of rhIL‐11 were not offset by the substantial cost of the pharmaceutical. The greater expected costs from the rhIL‐11 strategy were relatively insensitive to the unit price and efficacy of rhIL‐11 and the costs of platelet transfusions and monitoring. CONCLUSIONS From the payer's perspective, rhIL‐11 cannot be considered a cost‐saving clinical strategy compared with routine platelet transfusions for patients with severe chemotherapy‐induced thrombocytopenia. Cancer 2003;97:3099–106. © 2003 American Cancer Society. DOI 10.1002/cncr.11447Keywords
This publication has 19 references indexed in Scilit:
- Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer PatientsThe Oncologist, 2001
- Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Incidence, Cost, and Outcomes of Bleeding and Chemotherapy Dose Modification Among Solid Tumor Patients With Chemotherapy-Induced ThrombocytopeniaJournal of Clinical Oncology, 2001
- Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical TrialCancer Investigation, 2001
- Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double‐blind trialTransfusion, 2000
- Transfusion Medicine — Blood TransfusionNew England Journal of Medicine, 1999
- Leukocyte Reduction and Ultraviolet B Irradiation of Platelets to Prevent Alloimmunization and Refractoriness to Platelet TransfusionsNew England Journal of Medicine, 1997
- Cost-Effectiveness of Transesophageal Echocardiographic-Guided Cardioversion: A Decision Analytic Model for Patients Admitted to the Hospital With Atrial FibrillationJournal of the American College of Cardiology, 1997
- A Cost-Effectiveness Analysis of Epoetin Usage for Patients with AIDSPharmacoEconomics, 1993
- Incidence of hemorrhagic complications in patients with cancerJAMA, 1978